WALTHAM, Mass. – Thermo Fisher Scientific has officially shed its microbiology business to the tune of more than $1 billion.
The global pharmaceutical and biotechnology company announced the completion of the transaction this week with the European private equity firm Astorg.
Thermo Fisher made the sale for about $1.08 billion.
The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing. The business generated $645 million in revenue in 2025 and was part of Thermo Fisher’s Specialty Diagnostics segment, the company said.
Thermo Fisher is based in Massachusetts and has more than 600 sites around the world, including in Upper Saucon Township, East Allen Township and Upper Macungie Township.
A company spokesperson told 69 News the Lehigh Valley locations are not impacted by the sale of the microbiology business.